Cipla | CIPLA - Cost Of Sales


Cipla reported INR26.32B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
aTyr Pharma USD 3.34M 18.79M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 26.32B 2.79B Mar/2026
Dr.Reddys Laboratories INR 37.7B 1.54B Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Infinity Pharmaceuticals USD 352K 89K Jun/2023
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sun Pharmaceuticals INR 36.77B 348M Dec/2025
TherapeuticsMD USD -11.99M 12.34M Dec/2022
UPL INR 110.38B 43.65B Mar/2026